# Amyotrophic Lateral Sclerosis Association

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/amyotrophic-lateral-sclerosis-association/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 56.7 |
| Citations | 49,695 |
| City | Washington D.C. |
| Country | US |
| Description | Amyotrophic Lateral Sclerosis Association is a research organisation in Washington D.C., US. OpenAlex records 903 works and 49,695 citations for it. 356 researchers list it as their most recent affiliation. |
| Homepage | http://www.alsa.org/ |
| OpenAlex ID | https://openalex.org/I2802461698 |
| Region | District of Columbia |
| Researchers | 356 |
| ROR ID | https://ror.org/00mwp5989 |
| Type | nonprofit |
| Wikidata ID | https://www.wikidata.org/wiki/Q4652439 |
| Works | 903 |

## University papers

Showing 12 of 30.

- [Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study](https://scholariq.org/papers/frequency-of-the-c9orf72-hexanucleotide-repeat-expansion-in-patients-with/)
- [Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS](https://scholariq.org/papers/exome-sequencing-reveals-vcp-mutations-as-a-cause-of-familial-als/)
- [Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study](https://scholariq.org/papers/safety-and-efficacy-of-eculizumab-in-anti-acetylcholine-receptor-antibody/)
- [Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study](https://scholariq.org/papers/comparison-of-tocilizumab-monotherapy-versus-methotrexate-monotherapy-in/)
- [Genome-wide Analyses Identify KIF5A as a Novel ALS Gene](https://scholariq.org/papers/genome-wide-analyses-identify-kif5a-as-a-novel-als-gene/)
- [Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/safety-efficacy-and-tolerability-of-efgartigimod-in-patients-with-generalised/)
- [Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study](https://scholariq.org/papers/phenotypic-heterogeneity-of-amyotrophic-lateral-sclerosis-a-population-based/)
- [Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology](https://scholariq.org/papers/common-and-rare-variant-association-analyses-in-amyotrophic-lateral-sclerosis/)
- [Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model](https://scholariq.org/papers/prognosis-for-patients-with-amyotrophic-lateral-sclerosis-development-and/)
- [Projected increase in amyotrophic lateral sclerosis from 2015 to 2040](https://scholariq.org/papers/projected-increase-in-amyotrophic-lateral-sclerosis-from-2015-to-2040/)
- [Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis](https://scholariq.org/papers/mutations-in-the-matrin-3-gene-cause-familial-amyotrophic-lateral-sclerosis/)
- [NEK1 variants confer susceptibility to amyotrophic lateral sclerosis](https://scholariq.org/papers/nek1-variants-confer-susceptibility-to-amyotrophic-lateral-sclerosis/)

## University researchers

- [Andrea Calvo](https://scholariq.org/researchers/andrea-calvo/)
- [Umberto Manera](https://scholariq.org/researchers/umberto-manera/)

## University top topics

Showing 8 of 23.

- [Amyotrophic Lateral Sclerosis Research](https://scholariq.org/topics/amyotrophic-lateral-sclerosis-research/)
- [Neurogenetic and Muscular Disorders Research](https://scholariq.org/topics/neurogenetic-and-muscular-disorders-research/)
- [Parkinson's Disease Mechanisms and Treatments](https://scholariq.org/topics/parkinson-s-disease-mechanisms-and-treatments/)
- [Genetic Neurodegenerative Diseases](https://scholariq.org/topics/genetic-neurodegenerative-diseases/)
- [Palliative Care and End-of-Life Issues](https://scholariq.org/topics/palliative-care-and-end-of-life-issues/)
- [Neurological diseases and metabolism](https://scholariq.org/topics/neurological-diseases-and-metabolism/)
- [Alzheimer's disease research and treatments](https://scholariq.org/topics/alzheimer-s-disease-research-and-treatments/)
- [Prion Diseases and Protein Misfolding](https://scholariq.org/topics/prion-diseases-and-protein-misfolding/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.